ArticleFrontiers in endocrinology2025
Percutaneous ethanol and calcitriol injection therapy for hyperparathyroidism - a single-centre experience.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The purpose of this study is to evaluate the use of percutaneous ethanol and calcitriol injection therapy for hyperparathyroidism (HPT), while taking into account the efficacy, safety and feasibility as an ambulatory procedure alternative to surgical parathyroidectomy. Methods: We included nine patients who underwent percutaneous injection therapy for HPT from January 2018 to December 2021 in our institution. They were followed up from date of first percutaneous injection until death or October 2022 (mean duration of 9.0 months). Results: Four patients underwent percutaneous ethanol injection therapy (PEIT) (mean age 61.0 [31-89] years old), while the remaining five underwent percutaneous calcitriol therapy (PCIT) (mean age 62.6 [35-91] years old). The analyzed parameters are age, BMI, serum turn over markers as iPTH, Ca, alkaline phosphatase and vitamin D. Two out of the four patients undergoing PEIT had a successful outcome, although one needed to continue cinacalcet due to persistent serum calcium levels. Three out of five PCIT patients in our series had successful procedure, although one subsequently developed refractory disease. Conclusion: PEIT and PCIT are feasible and safe therapeutic alternatives to surgical parathyroidectomy in HPT refractory to medical treatment, with postulated benefits of decreased costs and being an outpatient procedure. However, further studies are necessary to evaluate the efficacy and cost-effectiveness with these techniques prior to widespread adoption.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.